Johnson & Johnson Bids $2.3 Billion for Dutch Biotech Crucell (JNJ)

By
A A A
Share |

Healthcare giant Johnson & Johnson ( JNJ ) on Friday said it is deep into talks to purchase Dutch biotech company Crucell for around US$2.3 billion.

JNJ already owns a 17.9% stake in Crucell, which makes vaccines and antibodies to help fight human diseases. The cash offer of 24.75 euros per share represents a 58% premium over Crucell's Thursday closing price.

Crucell CEO Ronald Brus said the company will recommend shareholders tender their shares to the offer, and noted the deal could close by the end of the year.


Johnson & Johnson shares were mostly flat in premarket trading Friday.

The Bottom Line
We have been recommending shares of JNJ since Oct.8, 2009, when the stock was trading at $60.71. The company has a 3.52% dividend yield, based on last night's closing stock price of $61.29.

Johnson & Johnson ( JNJ ) is a "recommended" dividend stock holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks: JNJ

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          

Stocks

Referenced

77%

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com